ClinicalTrials.gg
Active, not recruitingNCT05432544Updated Jul 6, 2023

Safety and Tolerability of SHR-1918 in Healthy Subjects

A Phase 1 interventional study of SHR-1918 and SHR-1918 placebo in Hyperlipemia, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 1 of them phase 3. Hyperlipidemias · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
8th of 14
72 · median 78
Started
2022
with 1 other
Phase 1
8 of 14
none open now
Registered
3rd of 14
by date

Among the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 1, and was the 3rd registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918 injection in healthy subjects.

03

Conditions studied

  • Hyperlipemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 and ≤65 on the date of signing the , males or females;
  2. 1.7 mmol/L≤TG≤5.6 mmol/L,2.6 mmol/L≤LDL-C\<4.9 mmol/L;
  3. Understand the study procedures and methods, volunteer to participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion Criteria:

-

1.History of disease or treatment for:

  1. Known allergic reaction to experimental drugs or severe allergic reaction to other antibody drugs;
  2. Malignncy;
  3. Combined cardiovascular, hepatic, renal, gastrointestinal, neuropsychiatric, hematological, or metabolic diseases;
  4. History of any drug use prior to screening or within 2 weeks prior to baseline

2.Any one of the following tests at screening :

  1. (ALT) or aspartate aminotransferase (AST) or gamma-glutamyl transferase (GGT) exceeding 2 times , or total exceeding 1.5 times ULN
  2. Creatine kinase (CK) exceeding 3 times the upper limit of normal (ULN)

3.General:

  1. History of drug or substance abuse;
  2. Average of 5 or more cigarettes per day during the 4 weeks prior to screening;
  3. History of blood donation within 3 months prior to screening, or severe blood loss (≥400 mL blood loss), or received a blood transfusion within 4 weeks;
  4. Vaccination within 2 weeks prior to screening or planned during the course of the trial

4.The Investigator determines that the subjects have poor compliance or have any factors that may prevent them from participating in the study, including, but not limited to, the study placing the subjects at unacceptable risk or possibly interfering with the study results.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    SAD, SHR-1918

    Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 injection

    Drug: SHR-1918

  • Placebo comparator
    SAD, SHR-1918 placebo

    Up to 6 cohorts of healthy subjects will receive a single dose of SHR-1918 placebo injection

    Drug: SHR-1918 placebo

Interventions

  • Ascending dose

  • DrugSHR-1918 placebo

    Ascending dose

06

What researchers measure

Primary outcomes

  1. To assess the number of subjects with adverse events (AEs)

    Time frame: up to day 190

  2. To assess the number of subjects with serious adverse events (SAEs)

    Time frame: up to day 190

Secondary outcomes

  1. To assess AUC0-t

    Time frame: up to day 190

  2. To assess AUC0-∞

    Time frame: up to day 190

  3. To assess Tmax

    Time frame: up to day 190

  4. To assess Cmax

    Time frame: up to day 190

  5. To assess t1/2

    Time frame: up to day 190

  6. To assess CL/F

    Time frame: up to day 190

  7. To assess 、V/F.

    Time frame: up to day 190

  8. To assess LDL-C

    Time frame: up to day 190

  9. To assess TC

    Time frame: up to day 190

  10. To assess HDL-C

    Time frame: up to day 190

  11. To assess TG

    Time frame: up to day 190

  12. To assess ApoB

    Time frame: up to day 190

  13. To assess ApoA1

    Time frame: up to day 190

  14. To assess Lp(a)

    Time frame: up to day 190

  15. To assess VLDL-C.

    Time frame: up to day 190

  16. To assess ADA(or/and Nab).

    Time frame: up to day 190

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's planned 17 months is above that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jun 27, 2022
StartActual
Jun 27, 2022
Primary completionEst.
Dec 11, 2023
CompletionEst.
Dec 12, 2023
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05432544
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Jun 27, 2022
Primary completion
Dec 11, 2023 (estimated)
Completion
Dec 12, 2023 (estimated)
Last update
Jul 6, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1918

Start the discussion